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Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with a very fast 
progression, no diagnostic tool for the presymptomatic phase, and still no effective 
treatment of the disease. Although ALS affects motor neurons, the overall patho-
physiological condition points out to the non-cell autonomous mechanisms, where 
astrocytes and microglia play crucial roles in the disease progression. We have already 
shown that IgG from sera of ALS patients (ALS IgG) induce calcium transients and 
an increase in the mobility of acidic vesicles in cultured rat astrocytes. Having in mind 
the role of microglia in neurodegeneration, and a well-documented fact that oxidative 
stress is one of the many components contributing to the disease, we decided to 
examine the effect of ALS IgG on activation, oxidative stress and antioxidative system 
of BV-2 microglia, and to evaluate their acute effect on cytosolic peroxide, pH, and on 
reactive oxygen species (ROS) generation. All tested ALS IgGs (compared to control 
IgG) induced oxidative stress (rise in nitric oxide and the index of lipid peroxidation) 
followed by release of TNF-α and higher antioxidative defense (elevation of Mn- and 
CuZn-superoxide dismutase, catalase, and glutathione reductase with a decrease of 
glutathione peroxidase and glutathione) after 24 h treatment. Both ALS IgG and control 
IgG showed same localization on the membrane of BV-2 cells following 24 h treatment. 
Cytosolic peroxide and pH alteration were evaluated with fluorescent probes HyPer 
and SypHer, respectively, having in mind that HyPer also reacts to pH changes. Out of 
11 tested IgGs from ALS patients, 4 induced slow exponential rise of HyPer signal, with 
maximal normalized fluorescence in the range 0.2–0.5, also inducing similar increase of 
SypHer intensity, but of a lower amplitude. None of the control IgGs induced changes 
with neither of the indicators. Acute ROS generation was detected in one out of three 
tested ALS samples with carboxy-H2DCFDA. The observed phenomena demonstrate 
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the potential role of inflammatory humoral factors, IgGs, as potential triggers of the 
activation in microglia, known to occur in later stages of ALS. Therefore, revealing the 
ALS IgG signaling cascade in microglial cells could offer a valuable molecular biomarker 
and/or a potential therapeutic target.
Keywords: amyotrophic lateral sclerosis, immunoglobulin g, hyPer, sypher, oxidative stress, antioxidative 
system, BV-2 microglia
inTrODUcTiOn
Amyotrophic lateral sclerosis (ALS) is an adult-onset fatal neu-
rodegenerative disease (1) characterized by loss of upper and 
lower motor neurons. Two clinically indistinguishable forms 
of ALS exist, sporadic (sALS) and familial (fALS), the latter 
comprising 5–10% of cases. Common hallmark of both sALS 
and fALS is neuroinflammation with astrogliosis, microgliosis, 
and infiltration of peripheral immune cells at the sites of neu-
rodegeneration (2–6). Thus, non-neuronal cells play a crucial 
role in ALS, contributing to motor neuron death via non-cell 
autonomous mechanisms (7, 8).
Microglial cells originating from the myeloid lineage (9–11) 
are considered to be the resident mononuclear phagocytes in the 
central nervous system (9, 11, 12) that participate in the mainte-
nance of tissue homeostasis and in immune defense of the brain 
(9, 12). In general, microglia contributes to the neuroinflamma-
tory response by rapid morphological and functional changes 
which include phagocytosis, antigen presentation, production 
and secretion of reactive oxygen species (ROS), cytokines, and 
growth factors (13–16). In ALS, especially regarding the familial 
form of the disease, animal models have shown that microglial 
activation begins at or before disease onset (2) and the number 
of activated cells increases during the disease progression (17). 
However, the late phase of disease progression in an animal 
model was slowed by selective excision of human mutant super-
oxide dismutase 1 SOD1 or Cu/ZnSOD gene from microglia 
and macrophage lineages, even when neurons are expressing 
high levels of the mutant gene (17) and diminished expression 
of mutant gene in astrocytes delays microglial activation (18).
Although the majority of studies are done on animal models 
with overexpressed human genes characteristic for fALS, with 
the rationale that hallmarks of both fALS and sALS are similar. 
Nevertheless, there were some attempts to explicitly model the 
sporadic form of the disease. For this purpose, investigators 
have used either cerebrospinal fluid (CSF) or purified immu-
noglobulins G (IgG) from sporadic ALS patients, and evaluated 
either the viability or electrophysiological properties of neuronal 
cells treated with human CSF/IgG [for review see Ref. (19) 
and references therein]. The data on glial cells in such models 
of sALS emerged in the recent years, but the focus was mainly 
on astrocytes. ALS IgG were found to increase the mobility of 
endosomes and lysosomes of primary astrocytes, suggesting 
the involvement of endocytotic/autophagic pathways (20). 
In addition, intracellular calcium homeostasis of rat astrocytes 
was acutely affected by ALS IgG (21). On the other hand, treat-
ment with sALS CSF caused disbalance in astrocytic cytokines, 
elevating production and release of proinflammatory, and 
decreasing anti-inflammatory cytokines and beneficial trophic 
factors, with impaired regulation of ROS, nitric oxide (NO), and 
glutamate (22). Elevated ROS and cellular peroxide levels, as well 
as increased mitochondrial SOD (MnSOD) activity were found 
in spinal cord extracts of pups intrathecally injected with sALS 
CSF (23), stressing out the role of oxidative stress. However, mice 
intraperitoneally injected with sALS IgG showed increased levels 
of both pro- and anti-inflammatory cytokines in the spinal cord, 
causing initial morphological and electrophysiological manifes-
tations of degeneration, but with no actual death of spinal motor 
neurons (24). On the other hand in the study by Pullen et  al. 
(25), ALS IgG inoculation caused motor neuron death, however 
with the different inoculation protocol and experimental time 
frame. These findings raise the question of the role of blood brain 
barrier impairment in ALS, with different manifestations of the 
leakage found in animal models and humans [for reviews see 
Ref. (19, 26)] that would favor entrance of humoral immune 
factors, e.g., IgG into the brain parenchyma, causing versatile 
effects on both neural and glial cells.
Oxidative stress has been assigned as one of the main causes 
of ALS (27–31), however, only a few studies on the ALS rat 
model could actually demonstrate a change in redox state 
in vivo (32). It was thus of particular interest to search for the 
missing link between the inflammatory humoral factors, ALS 
IgGs and oxidative stress. Having in mind the crucial role of 
microglia in onset and progression of the disease in animal 
models of ALS, we were interested in evaluating the extent of 
ALS IgG effect on this cell type. For that purpose, we acutely 
treated the BV-2 microglial cell line with ALS IgGs and meas-
ured their ROS response with fluorescence dyes, and monitored 
cytosolic peroxide and pH with genetically encoded sensors. In 
addition, the release of inflammatory factors and the expres-
sion of the antioxidative defense molecules has been checked by 
biochemical and molecular genetics assays. It has been shown 
that ALS IgGs do induce an acute effect on intracellular ROS 
production followed by cellular alkalization as well as a later 
induction of molecules of the inflammatory as well as of the 
antioxidant pathways.
MaTerials anD MeThODs
Blood samples and igg isolation
Blood samples were collected from clinically diagnosed sporadic 
(sALS) and familial (fALS) ALS patients and age-matched dis-
ease and healthy controls at the Institute of Neurology, Clinical 
Center of Serbia. Human sera from 20 ALS patients (3 fALS 
and 17 sALS; 13 males and 7 females) of age 59.6 ± 2.5 years 
TaBle 1 | List of samples used in experiments.
Patient Disease alsFrsr age sex Used
#1 sALS 46 64 F H
#2 sALS 45 64 M H, B
#3 fALS (SOD 1 D90A) 45 69 M X
#4 sALS 43 54 M C, X
#5 sALS 42 42 M I, E, B
#6 sALS 42 71 F X
#7 sALS 41 67 M H
#8 sALS 41 65 M H
#9 sALS 40 62 M H, B
#10 sALS 40 60 M C, I, X
#11 sALS 38 70 M H
#12 sALS 37 50 M E, B
#13 sALS 37 67 F X
#14 fALS (C9orf72) 36 34 F H, B
#15 sALS 36 41 M H
#16 sALS 35 71 M C, I, X
#17 sALS 34 68 F E, B
#18 sALS 34 62 F H, B
#19 sALS 33 46 F H, B
#20 fALS (C9orf72) 28 64 M H, B
#21 Healthy – 57 F B
#22 Healthy – 57 F H
#23 Healthy – 49 M H, B
#24 Healthy – 63 M H, B
#25 Polyneuropathy – 67 M E, B
#26 Polyneuropathy – 41 M E, B
#27 Polyneuropathy – 74 M X
#28 Polyneuropathy – 64 M C, I, X
#29 Nonspecific ataxia – 58 M I, X
#30 Discopathy of cervical spine – 44 M H
#31 Discopathy of thoracal spine – 57 F H
Patients are scored on the ALS revised functional rating scale (ALSFRSr) reflecting 
the stage of the disease (lower scores indicate disease progression). sALS, sporadic 
ALS; fALS, familial ALS (with type of mutation indicated in the brackets). Labels of 
experiments in which particular samples were used are: H, HyPer&SypHer; C,  
carboxy-H2DCFDA; I, immunocytochemistry; E, ELISA; X, expression (RT-qPCR);  
B, biochemistry.
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(mean ± SEM) with the average score of 38.7 ± 1.0 on the ALS 
functional rating scale according to the El Escorial revised criteria 
for the diagnostics of ALS (33) and 11 controls (four healthy and 
seven disease controls; details in Table 1), age 57.4 ± 3.0 years, 
were collected for routine clinical examination with informed 
patient’s consent in accordance with The Code of Ethics of the 
World Medical Association (Declaration of Helsinki) for experi-
ments involving humans. The protocol was approved by the 
Ethics committee of the Clinical Center of Serbia (No. 1985/5). 
A part of biological material was used for IgG isolation at the 
Institute of Virology, Vaccines and Sera-Torlak, Belgrade, Serbia 
as described previously (20).
cell culture and Treatments
In this study, we used microglial BV-2 cell line, frequently used 
as substitute for primary microglia, derived from raf/myc-
immortalized murine neonatal microglia (34). Cells were used in 
passages 5–15. BV-2 cell line was maintained in growth medium 
consisting of RPMI with l-glutamine, and sodium pyruvate 
(Sigma Aldrich, Germany), supplemented with 25 mM HEPES, 
10% fetal bovine serum (Gibco, Invitrogen, USA), and penicil-
lin/streptomycin (Gibco, Invitrogen, USA) at 37°C in humidified 
incubator with 5% CO2. After the cells reached ~90% confluence, 
they were washed with PBS, trypsinized (0.25% trypsin and 0.02% 
EDTA), centrifuged (500  g, 5  min), and then passaged and/or 
plated for the experiments. For biochemical analysis, cells were 
plated on 24-well plates (6 × 104 cells/well) in 0.5 ml of growth 
media, while for the expression analysis, BV-2 microglial cells 
were plated on 6-well plates (3 × 105 cells/well) in 2 ml of growth 
media. On the following day, the culture medium was replaced 
with the culture medium containing ALS IgG (0.1  mg/ml) or 
control IgG (0.1  mg/ml) and cells were kept for the indicated 
period of time (4 or 24  h). The IgG concentration tested was 
selected from our previous studies on neuronal and glial cells 
in culture (20, 21, 35). Cells kept in medium without IgG were 
used as a control.
Measurement of nO Production
BV-2 cells (6 × 104 cells/well) were plated and treated for 24 h 
(here and in Sections “Malondialdehyde (MDA) Determi-
nation” to “Total Glutathione Determination,” at least in 
dup licate for each IgG) as described. After the indicated time 
supernatants were discarded, cells were washed in ice-cold PBS 
then collected with plastic scraper, lysed by sonication and 
centrifuged at 15,000 g for 5 min at 4°C for NO determination. 
NO is a highly unstable molecule and therefore the production 
was determined indirectly by measuring nitrite concentration 
spectrophotometrically at 492  nm using Griess method, after 
reducing nitrates to nitrites by cadmium reduction (36). Results 
are expressed as mean nitrite concentration (μM) ±  SEM for 
each group.
Malondialdehyde (MDa) Determination
BV-2 cells (6 × 104 cells/well) were plated and treated for 24 h 
and collected for measurements as described. MDA content 
was determined by the spectrophotometric method of Vilicarra 
et al. (37). First, thiobarbituric acid (TBA) reagent (15% trichlo-
racetic acid and 0.375% TBA water solution, Merck-Darmstadt, 
Germany) was mixed with cell lysate, heated to 95°C, centrifuged, 
and then the absorbance was measured at 532 nm. Results are 
expressed as mean MDA concentration (nmol/ml) ±  SEM for 
each group.
sOD activity Determination
BV-2 cells (6 × 104 cells/well) were plated and treated for 24 h, 
then collected for measurements as described. Total SOD activ-
ity, which combines the activity of two isoforms, MnSOD and 
cytoplasmic SOD (Cu/ZnSOD), was determined by epinephrine 
method. SOD activity was determined by spectrophotometric 
measurement of a decrease in the rate of the spontaneous 
epinephrine autooxidation at 480  nm. The kinetics of enzyme 
activity was followed in 50 mM carbonate buffer (pH 10.2) with 
1 mM EDTA after the addition of 10 mM epinephrine and 5 mM 
KCN for MnSOD (38). Cu/ZnSOD activity was determined as a 
difference between total SOD and MnSOD activity. Results are 
presented as units per milligram of total protein (U/mg). One 
unit is described as an amount of protein (enzyme) required for 
50% inhibition of autooxidation of epinephrine. Total protein 
concentration was determined by Lowry method (39).
TaBle 2 | List of primers used for real-time PCR.
Target gene reverse primer Forward primer annealing T (°c)
MnSOD CAGACCTGCCTTACGACTATGG CTCGGTGGCGTTGAGATTGTT 60
CAT AGCGACCAGATGAAGCAGTG TCCGCTCTCTGTCAAAGTGTG 60
GPx AGTCCACCGTGTATGCCTTCT GAGACGCGACATTCTCAATGA 60
NOX2 GGGAACTGGGCTGTGAAT CAGTGCTGACCCAAGGAGTT 60
NHE1 GCCTCATGAAGATAGGTTTCCA ACGTCTGATTGCAGGAAGGG 60
TNF-α CTGAACTTCGGGGTGATCGG GGCTTGTCACTCGAATTTTGAGA 60
GAPDH GTTGTCTCCTGCGACTTCA TGGTCCAGGGTTTCTTACTC 60
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catalase (caT) activity Determination
Catalase activity was assayed by a method based on spectropho-
tometric determination of colored complex formed between 
ammonium molibdate and H2O2 at 405 nm (40). The results are 
expressed as units per milligram of total protein (U/mg), whereas 
the unit represents an amount of H2O2 reduced per min (μM 
H2O2/min).
glutathione Peroxidase (gPx) activity 
Determination
Glutathione peroxidase activity was assayed by indirect method 
that is based on spectrophotometric measurement of NADPH 
oxidation by glutathione reductase (GR) at 340  nm (41, 42). 
Briefly, GPx catalyzes the oxidation of GSH to GSSG which is then 
recycled back to GSH by GR. In that process GR reduces NADPH 
coenzyme, as a donor of reducing equivalents, to NADP+. The 
results are expressed as units per milligram of proteins (U/mg), 
whereas one unit represents an amount of reduced NADPH per 
min (μM NADPH/min).
gr activity Determination
Activity of GR was determined using method that is based 
on fluorimetric measurement of GR-mediated NAPDH oxidation 
to NADP+ (43). Decrease in NADPH fluorescence was measured 
with excitation/emission of 360/460  nm. We used 100  mM 
NAD+ as a standard in the reaction. Results are expressed as units 
per milligram of proteins (U/mg). One unit is described as an 
amount of oxidized NAPDH per min (μM NADPH/min).
Total glutathione Determination
BV-2 cells (6 × 104 cells/well) were plated and treated for 24 h, 
then collected for measurements as described. Intracellular glu-
tathione content was assessed by DTNB-GSSG reductase recycling 
assay (44). The formation of 5-thio-2-nitrobenzoic acid (TNB), 
which is proportional to total glutathione content in the sample, 
was measured spectrophotometrically at 412 nm for 6 min. Total 
glutathione concentration in samples was determined from 
standard curve constructed with known GSSG concentrations. 
Results are expressed as mean total glutathione concentration 
(nmol/ml) ± SEM for each group.
Quantitative real-time Pcr
BV-2 cells (3 × 105 cells/well) were plated, treated for 4 h with 
ALS IgG or control IgG (in duplicate for each IgG) and then 
collected. Total mRNA isolation was performed by using TRIzol 
reagent (Invitrogen, USA). The RNA content was quantified 
spectrophotometrically at 260  nm and 1  µg of RNA was used 
for reverse transcription with High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, USA). 
Real-time PCR amplifications were performed with SensiFAST™ 
SYBR® Hi-ROX Kit (Bioline, United Kingdom) and specific 
primers (sequences and annealing temperatures are given in 
Table  2, Invitrogen, USA), with QuantStudio TM Real-Time 
PCR System (Applied Systems, USA). The results were analyzed 
by using 2−ΔΔCt method. In previous experiments on BV-2 cells it 
was shown that there is no change in GAPDH, ACTB, and HPRT 
gene expression following LPS stimulation of these cells (Bozic, 
unpublished), therefore we used GAPDH and ACTB genes 
expression as internal controls. Since there were no differences, 
only results with GAPDH gene expression as an internal control 
are presented.
enzyme-linked immunosorbent  
assay (elisa)
BV-2 cells (6 × 104 cells/well) were seeded and treated with ALS 
IgG or control IgG (in triplicate for each IgG) for 24 h as previously 
described. After the indicated time supernatants were collected 
and TNF-α concentration was determined by ELISA by using 
detection and capture antibody (eBioscience, Germany) accord-
ing to the manufacturer’s protocol. After applying biotinylated 
capture antibody, avidine-HRP complex was added, and subse-
quently chromogenic substrate 3,3′,5,5′-tetramethylbenzedine 
(eBioscience, Germany). The reaction was stopped by adding 
1  M H3PO4 and absorbance was measured at 450  nm. TNF-α 
concentration was determined from standard curve constructed 
with known murine recombinant TNF-α concentrations. Results 
are expressed as mean concentration (pg/ml) ±  SEM for each 
group.
immunocytochemistry and confocal 
Microscopy
BV-2 cells were plated onto PLL-coated 10  mm circular glass 
coverslips (1.5 × 104 per coverslip). On the following day, cells 
were treated with human IgG (0.1  mg/ml, ALS or control, in 
growth media; in duplicate for each IgG) for additional 24  h. 
After treatment, cells were briefly washed with PBS, fixed in 4% 
PFA for 15 min, and washed in PBS. Then, the cell membrane was 
labeled with Wheat Germ Agglutinin, Tetramethylrhodamine 
Conjugate (WGA, 1:2,000; Molecular Probes, Thermo Fisher 
Scientific) for 10  min. Next, cells were permeabilized with 
0.05% Triton X-100 for 15 min, following washing in PBS. Cells 
were then labeled with secondary antibody, goat anti-human 
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IgG AlexaFluor 633 (1:200, Molecular Probes, Thermo Fisher 
Scientific) for 1 h in the dark at 37°C. After several washing steps 
with PBS, coverslips were incubated for 10 min with a nuclear 
counterstain (DAPI, 1:4,000), washed again thoroughly, and 
mounted on microscopic slides using Mowiol 4-88 mounting 
medium (Sigma Aldrich, Germany). Control staining was done 
by omitting IgG from the treatment.
Stained cells were visualized on a confocal laser-scanning 
microscope (LSM 510, Carl Zeiss GmbH, Jena, Germany) 
equipped with HeNe (543 and 633  nm) lasers. Oil-immersion 
objective 63×/NA 1.4 was used, and pinhole was set to 2.2 µm for 
both detection channels.
rOs imaging and Data analysis
For live cell imaging BV-2 cells were seeded onto 7 mm (6 × 103 
cells) or 10 mm (1.5 × 104 cells) round glass coverslips (Menzel 
Glasser, Germany), coated with poly-l-lysine (50 µg/ml, Sigma 
Aldrich, Germany). For each IgG sample 1–4 coverslips were 
prepared. The number of analyzed cells [region of interest (ROI)] 
is indicated in figures. In order to evaluate acute hydrogen per-
oxide production in response to IgG treatment, BV-2 cells were 
transfected with HyPer, a genetically encoded sensor for H2O2 
with expanded dynamic range (45), pC1-HyPer-2 (Addgene 
plasmid # 42211). Since HyPer shows pH dependence, a set 
of control experiments were done with BV-2 cells transfected 
with SypHer, peroxide-insensitive version of HyPer (46), pC1-
HyPer-C199S (Addgene plasmid # 42213). Transfection was 
done with Lipofectamine (LTX, Invitrogen, USA), or Turbofect 
(Thermo Fisher Scientific, USA), 24  h after plating, and cells 
were imaged on the following day. In addition, 6-carboxy-2′, 
7′-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA, 
Molecular Probes, Thermo Fisher Scientific, USA) a general oxi-
dative stress indicator was used to detect acute generation of ROS 
following treatment with IgG. BV-2 cells (24–48 h after plating) 
were loaded with 50 µM carboxy-H2DCFDA in working solu-
tion for 30 min. Cells were briefly rinsed three times and imaged 
immediately.
Transfected or dye-loaded coverslips were transferred 
into the recording chamber supplied with 1  ml of working 
solution, placed on an inverted epifluorescent microscope 
(AxioObserver A1, Carl Zeiss, Germany) equipped with 
water, glycerin, and oil immersion objective LD LCI Plan-
Apochromat 25x/0.8 (Carl Zeiss, Germany) and combined 
with VisiFluor Imaging System. The excitation light source 
was Xenon Short Arc lamp (Ushio, Japan) combined with high 
speed polychromator system (VisiChrome, Visitron Systems, 
Germany). The excitation light (480 nm) and the emission light 
passed through the FITC filter set (Chroma Technology Inc., 
USA). Time-lapse images were obtained by “evolve”-EM 512 
Digital Camera System (Photometrics, USA) via VisiView high 
performance imaging software (Visitron Systems, Germany). 
Initially, fluorescence intensities were recorded for 2–5 min to 
determine the baseline fluorescence (F0). Thereafter, human IgG 
(0.1 mg/ml) in working solution (1 ml) were applied directly 
to the imaged cells by customized delivery system, via glass 
pipettes (0.8 mm inner diameter, positioned ~350 μm away and 
~1 mm above the cells, at the angle of 45°) connected to High 
Speed Solution Exchange System (ALA Scientific Instruments, 
USA) with pinch valves and VC3 electronic valve controller. 
The volume in the recording chamber was kept at ~1  ml by 
suction from the top of solution. The response of cells to IgG 
was recorded for additional 5–10  min, followed by several 
minutes of constant perfusion of working solution (washing 
step), after which the cells were stimulated by H2O2 (100 µM 
or 4 mM) for 3–10 min, and washed again with working solu-
tion. In another set of experiments after recording fluorescence 
intensities for 2–5 min, 30 mM NH4Cl in working solution was 
applied for 4 min and then washed with working solution for 
several minutes.
The working solution consisted of NaCl (152  mM), KCl 
(2.5 mM), CaCl2 (2 mM), MgCl2 (1 mM), d-glucose (10 mM), 
and HEPES (10 mM), pH 7.4, adjusted with NaOH. The osmo-
lality of solution was ~300 mOsM, measured by vapor pressure 
osmometer (Vapro 5520, Wescor, USA).
After the experiment, the analysis began with extracting 
average fluorescence intensities from ROI that were drawn 
around each cell, in each time point of the experiment. 
Additionally, several ROIs were extracted from the background. 
The background correction was done by subtracting averaged 
background fluorescence from each ROI in every time point. 
Time sets of data from each ROI, corrected for background 
were further normalized to the baseline fluorescence (F0). 
Normalized fluorescence data, were expressed as ΔF/F0, where 
ΔF represents the change in fluorescence emission from the 
baseline fluorescence.
statistical analyses
Effects of ALS IgG and control IgG on NO, MDA and GSH levels, 
antioxidative enzymes gene expression and activities, NADPH 
oxidase 2 (NOX2) and Na+/H+ exchanger 1 (NHE1) gene expres-
sion and TNF-α gene expression and release were analyzed by 
comparing the means (absolute values) by one-way ANOVA, 
followed by Bonferroni post hoc test, with a significance level of 
p < 0.05. Acute effects of ALS and control IgG on ROS, H2O2 and 
pH were analyzed by comparing the amplitudes in certain time 
points (normalized fluorescence − ΔF/F0) by two-tailed Student’s 
t-test, with a significance level of p < 0.05. All mean values were 
presented as ±SEM.
resUlTs
Production of Markers of Oxidative  
stress (nO and MDa) is increased by  
als igg in BV-2 cells
Production of NO and the intracellular level of MDA were 
analyzed as they are relevant oxidative stress indicators. MDA 
is an end product of cell membrane phospholipids degradation 
and therefore is used as an index of lipid peroxidation (47). In 
this set of experiments, we treated BV-2 cells with ALS IgG iso-
lated from nine different patients (seven sALS and two fALS) 
with an average ALSFRSr 36.6 ± 1.7, aged 54.7 ± 4.0 years and 
with IgG from age-matched control subjects (three healthy and 
two disease controls, Table 1), and 24 h after the treatments 
FigUre 1 | Immunoglobulin G (IgG) isolated from amyotrophic lateral sclerosis (ALS) patients increase the production of nitric oxide (NO) and malondialdehyde 
(MDA) in BV-2 cells. NO production (a) and MDA production in BV-2 cells (B) were measured 24 h after treatments with control IgG and ALS IgG (0.1 mg/ml).  
NO production was measured indirectly using Griess assay and is expressed as NO2− concentration. The results for each group are presented as mean ± SEM; 
***p < 0.001 compared with untreated control group, ###p < 0.001 compared with the group treated with control IgG. The numbers in brackets indicate the  
number of different control IgG and ALS IgG samples examined and the number of untreated controls.
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cell lysates were collected for further examination. As shown 
in Figure  1A both ALS IgG and control IgG treatments 
resulted in a significant increase of NO production relative 
to untreated control (87.13 ±  4.52 and 36.07 ±  4.86 relative 
to 11.69 ±  0.53  µM; p <  0.001 and p <  0.05, respectively). 
Furthermore, ALS IgG caused 2.4-fold higher NO production 
than control IgG (p <  0.001). Similarly, treatment with ALS 
IgG induced a higher level of MDA compared with untreated 
cells and cells treated with control IgG (0.64 ±  0.03 relative 
to 0.31  ±  0.01 and 0.39  ±  0.01  nmol/ml, both p  <  0.001; 
Figure 1B).
als igg enhance the antioxidative 
system in BV-2 cells
To examine the effect of IgG on the antioxidative system in 
BV-2 cells, we measured the activity of antioxidative enzymes 
(MnSOD, Cu/ZnSOD, CAT, GR, GPx) as well as the total 
intracellular glutathione content. BV-2 cells were treated 
for 24  h with ALS IgG from nine different patients and age 
matched controls (all same as above, Table  1). Results show 
that MnSOD and Cu/ZnSOD activities were significantly 
elevated, in ALS IgG-treated cells compared with untreated 
control (102.18 ± 3.98 vs. 52.53 ± 2.27 U/mg and 556 ± 15.12 
vs. 279.64 ± 3.92 U/mg, respectively, both p < 0.001). In addi-
tion, both enzymes’ activities were significantly higher in ALS 
IgG-treated compared with control IgG-treated cells (1.4-fold, 
p < 0.001 and 1.2-fold, p < 0.01, respectively; Figures 2A,B). 
Similarly, CAT activity was increased in BV-2 cells treated 
with ALS IgG (121.72 ± 6.14 U/mg, that was 1.5-fold higher as 
compared with the control group, 82.78 ± 1.18 U/mg, p < 0.01, 
and 1.2-fold higher as compared to cells treated with control 
IgG, 100.85 ±  5.41  U/mg, but with no statistical significance; 
Figure 2C). On the other hand, we observed a decreased GPx 
activity after ALS IgG treatment in comparison with the untreated 
group (88.42 ± 1.79 vs. 99.28 ± 2.46 U/mg, p < 0.05), however, 
we did not observe a significant difference from the activity in 
control IgG (93.35 ± 2.11 U/mg), all shown in Figure 2D. IgG 
treatments (ALS and control) also increased GR activity com-
pared with the control group (33.33 ± 1.03 U/mg, p < 0.001 and 
p < 0.05, respectively), while ALS IgG induced a 1.5-fold higher 
acti vity (70.44 ± 2.04 U/mg) than control IgG (46.58 ± 1.8 U/mg, 
p  <  0.0001), all shown in Figure  2E. Finally, we measured 
total intracellular glutathione content and found that it was 
decreased after both ALS IgG (4.18 ± 0.25 nmol/ml) and control 
IgG treatments (5.09  ±  0.29  nmol/ml) compared with the 
untreated group (6.61 ±  0.21  nmol/ml, p <  0.001, p <  0.05, 
respectively). Although there was no statistical significance, 
there was a trend of a decrease in total glutathione content 
after ALS IgG treatment compared with control IgG treatment 
(Figure 2F).
expression of genes for antioxidative 
enzymes, nOX2 and nhe1 following  
als igg Treatment
To further examine the effect of ALS IgG on the antioxidative 
system of BV-2 cells, we determined the gene expression levels 
for MnSOD, CAT, and GPx by qRT-PCR. BV-2 cells were treated 
with human IgG and the mRNA content was determined 4  h 
after the treatment (Figure  3). In this set of experiments, we 
used IgG from 6 different ALS patients (ALSFRSr 40.3 ±  1.5, 
aged 65.3  ±  2.8  years) and IgG from three disease controls 
(aged 65.3 ±  4.7 years, Table 1). Analysis of the results shown 
in Figure  3A indicates that neither ALS IgG nor control IgG 
induced significant changes in MnSOD expression compared 
with untreated control. Interestingly, MnSOD gene expression 
was only upregulated (approx. 3.5-fold) after treatment with 
ALS IgG from a patient having fALS with ALSFRSr 45 (sample 
#3 in Table 1). Following a 4 h ALS IgG treatment, there were 
also no significant changes in expression of CAT and GPx genes 
(Figures 3B,C).
Furthermore, we wanted to examine the effect of ALS IgG 
on the gene expression for NOX2, an enzyme that produces 
O2− and therefore is a potential oxidative stress inducer. We did 
FigUre 2 | Immunoglobulin G (IgG) isolated from amyotrophic lateral sclerosis (ALS) patients increase antioxidative enzymes activities and decrease total 
glutathione content in BV-2 cells. Mitochondrial superoxide dismutase (MnSOD) (a), cytosolic SOD (Cu/ZnSOD) (B), catalase (CAT) (c), glutathione peroxidase 
(GPx) (D), glutathione reductase (GR) activity (e), and total glutathione content in BV-2 cells (F) were measured 24 h after ALS IgG and control IgG treatments  
(0.1 mg/ml). The results of antioxidative enzymes activities for each group are presented as mean specific activities per milligram of total proteins (U/mg) ± SEM  
and total glutathione content is presented as mean concentration in nmol/ml ± SEM; **p < 0.01 ***p < 0.001 compared with untreated control group, #p < 0.05, 
###p < 0.001, compared with the group treated with control IgG. The numbers in brackets indicate the number of different control IgG and ALS IgG samples 
examined and the number of untreated controls.
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not observe any notable difference in gene expression after ALS 
IgG treatment when compared to either control IgG treated 
or untreated control group. However, ALS IgG from the fALS 
patient with ALSFRSr 45 (sample #3 in Table  1) induced an 
approx. threefold increase in NOX2 gene expression as com-
pared to control IgG (Figure  3D), resembling the effect on 
MnSOD gene expression (Figure 3A). Finally, we analyzed the 
effect of ALS IgG on gene expression of NHE1which may be a 
regulator of NOX2 activity (48), however, we did not find any 
significant alterations when compared either with control IgG 
or the untreated control.
als igg Modulates the release of TnF-α
The inflammatory potential of ALS IgG was evaluated by deter-
mining their effect on the TNF-α release and gene expression 
following 24 and 4 h treatments, respectively, using the same sam-
ples as in evaluating activity of antioxidative enzymes. ALS IgG-
treatment induced a rise in TNF-α release (454.31 ± 42.75 pg/ml) 
compared with control IgG-treated group (160.88 ± 10.37 pg/ml, 
p < 0.05) as well as with the untreated group (15.15 ± 9.76 pg/ml, 
p  <  0.01), as seen in Figure  4A. The results of the TNF-α 
gene expression experiments showed no difference between 
the groups. Interestingly, ALS IgG from the fALS patient with 
FigUre 4 | Effect of amyotrophic lateral sclerosis (ALS) immunoglobulin G (IgG) on release and gene expression of proinflamatory cytokine TNF-α. (a) BV-2 cells 
were treated with ALS IgG or control IgG for 24 h. Levels of TNF-α in culture medium after applied treatments were determined by enzyme-linked immunosorbent 
assay (ELISA). Culture medium from untreated cells was used as a control. Data are presented as mean TNF-α (pg/ml) ± SEM for each group. The numbers in 
brackets indicate the number of different control IgG and ALS IgG samples examined and the number of untreated controls. Significance level showed inside the 
graphs: **p < 0.01 compared with untreated control group, #p < 0.05 compared with the group treated with control IgG (B) mRNA expression of TNF-α gene after 
4 h ALS IgG or control IgG treatment was determined by RT-qPCR and expressed relative to the GAPDH gene expression. Untreated cells were used as a control. 
The data are represented as individual values obtained for each IgG and control. Red dot represents gene expression of TNF-α after treatment with ALS IgG from 
fALS patient (sample #3; see Table 1) and is not included in mean value (line). Other ALS samples used were #4, #6, #10, #13, and #16 (see Table 1).
FigUre 3 | Effect of amyotrophic lateral sclerosis (ALS) immunoglobulin G (IgG) on gene expression of antioxidative enzymes, NOX2, and NHE1 in BV-2 cells. 
Expression of mitochondrial superoxide dismutase (MnSOD) (a), catalase (CAT) (B), glutathione peroxidase (GPx) (c), NOX2 (D), and NHE1 (e) was determined by 
RT-qPCR following 4 h ALS IgG or control IgG treatment. Untreated cells were used as a control. mRNA expression of these genes was expressed relative to the 
GAPDH gene expression, as an internal control. The data represent gene expression obtained for each IgG and untreated control. Red dot in ALS IgG group 
represents results obtained after treatment with ALS IgG from a fALS patient (sample #3; see Table 1) and is not included in calculation of mean value (line). Other 
ALS samples used were #4, #6, #10, #13, and #16 (see Table 1).
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ALSFRSr 45 (sample # 3 in Table 1) caused a marked increase 
in TNF-α gene expression (Figure 4B).
human igg colocalize with Membrane  
of BV-2 cells after 24 h Treatment
Previous results have shown that ALS IgG increase the markers 
of oxidative stress, but also enhance the antioxidative system in 
BV-2 cells after 24 h treatment. Although control IgGs differ in 
effect from ALS IgG, the treatment with control IgG increased 
NO production, as well as the activity of Mn and Cu/ZnSOD and 
GR, and decreased total glutathione content. Since both ALS and 
control IgGs affected BV-2 cells after 24  h treatment, we were 
interested to evaluate the localization of human IgG in BV-2 cells 
following 24 h incubation. For this purpose, cells were fixed after 
FigUre 5 | Immunocytochemical localization of immunoglobulin G (IgG) after 24 h treatment of BV-2 cells. BV-2 cells were treated with amyotrophic lateral sclerosis 
(ALS) (sample #16; second row) or control IgG (sample #28; first row) for 24 h. After the treatment, cells were fixed and labeled with WGA (red; membrane marker) 
and anti-human IgG (green). Colocalization of both markers is indicated by yellow in the merge column. Scale bar 20 µm.
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treatment with human IgG (three ALS, two control IgG, details 
in the Table 1), and stained with WGA, the membrane marker, 
while IgGs were visualized with fluorescent secondary antibody 
against human IgG. Interestingly, both ALS and control IgGs 
showed similar staining pattern on BV-2 cells, and these humoral 
immune factors could be visualized mostly on the cellular 
membrane (Figure 5). We did not detect any substantial changes 
in the shape of BV-2 cells in any of the treatments compared to 
the untreated control (data not shown). The cells were mostly of 
round morphology in the middle focal plane (as represented in 
the micrographs of Figure 5).
als igg acutely increase the ph of  
BV-2 cells Which is accompanied with 
elevated cytoplasmic Peroxide
All the effects of ALS IgGs so far were evaluated after 4 or 24 h 
treatments. Hence, we were interested to see if there are any 
acute effects of human IgG on BV-2 cells. For this purpose, we 
used an epifluorescent imaging system, and plasmids coding 
for probes sensitive to peroxide (HyPer) and pH (both HyPer 
and SypHer). In this set of experiments, we used samples from 
11 ALS patients (9 sALS and 2 fALS) with an average ALSFRSr 
38.0 ±  1.6, aged 58.1 ±  3.6  years and IgG from age-matched 
control subjects (3 healthy and 2 disease controls, Table 1). Four 
ALS IgG (36.36%; three sALS and one fALS) induced acute rise 
in HyPer fluorescence intensity immediately after the application 
of IgG that continued to increase throughout the 5 min period, 
decreased slowly during the wash period, and rose again during 
the application of 100  µM H2O2 (Figures  6A–D, red traces). 
HyPer is a very sensitive indicator of peroxide, but since it is also 
sensitive to pH changes, control experiments were done with 
the same ALS samples on BV-2 cells transfected with SypHer 
that reacts only to the pH changes (peroxide sensing part in the 
plasmid is mutated). Interestingly, all four ALS samples induced 
an increase in SypHer intensity in the similar manner (although 
with the lower averaged amplitude), the intensity decreased 
during the washing period, and as expected, no change in 
fluorescence intensity could be detected in response to 100 µM 
peroxide (Figures  6A–D, blue traces). None of the control 
IgGs induced changes in HyPer intensity (example shown in 
Figure 6E). Since both plasmids have the same spectral char-
acteristics, their response could be evaluated only on separate 
coverslips with cells, so we wanted first to evaluate the similarity 
of response of these two sensors to the same pH perturbation, 
induced by 30 mM NH4Cl. As expected, ammonium-chloride 
induced a very sharp increase in the fluorescence intensity 
(indicating increase in the cytosolic pH) followed by a slow 
decay during the stimulation with 30 mM NH4Cl (Figure 6F). 
The removal of ammonium-chloride was accompanied by sharp 
decay in fluorescence intensity (indicating decrease in cytosolic 
pH) that slowly returned to the baseline (Figure 6F). The ampli-
tudes of maximal normalized fluorescence intensity in response 
to alkalization were measured in both cases of transfected 
cells, with HyPer (0.48 ± 0.02; n = 4) and SypHer (0.55 ± 0.03; 
n = 6), and the analysis showed no difference between the two 
groups (two-tailed t-test, p = 0.145; Figure 6G). Since the two 
sensors react in the same manner to pH changes, the attribution 
of peroxide to HyPer intensity changes could be determined 
by subtraction of SypHer from HyPer intensity. By comparing 
the intensities in the fifth minute after ALS IgG application 
(maximal measured intensity), the difference between HyPer 
and SypHer was greater than 10% only in the case of sample #7 
(Figure 6B, 17% difference).
FigUre 6 | Accute effect of amyotrophic lateral sclerosis (ALS) immunoglobulin G (IgG) on pH change, peroxide production, and reactive oxygen species (ROS) 
generation in BV-2 cells. (a–F) BV-2 cells were transfected with HyPer (red trace; peroxide and pH sensitive) or SypHer (blue trace; pH sensitive). (a–D) Averaged 
fluorescence of BV-2 cells treated with ALS IgG for 5 min (indicated by cyan box) followed by washing and treatment with 100 µM H2O2 (indicated by magenta box). 
HyPer transfected cells show rise in fluorescence intensity when challenged both by ALS IgG and H2O2, while SypHer transfected cells increase the fluorescence 
intensity when challenged with ALS IgG only. The difference in ALS IgG treated HyPer and SypHer traces is significant in panel B. Number of cells is indicated in 
brackets. Samples #14 (a), #7 (B), #11 (c), and #9 (D) were used for treatments. (e) Averaged fluorescence of HyPer transfected BV-2 cells treated with control 
IgG (sample #30) for 5 min (indicated by cyan box), followed by washing and treatment with 100 µM H2O2 (indicated by magenta box). (F) Representative traces of 
HyPer and SypHer transfected BV-2 cells treated with 30 mM NH4Cl (indicated by yellow box). (g) Comparison of the amplitudes of maximal fluorescence increase 
of HyPer and SypHer transfected BV-2 cells treated with 30 mM NH4Cl. Both plasmids show similar sensitivity to pH change. Number of cells is indicated in the 
base of the histogram bars. (h) BV-2 cells were loaded with Carboxy-H2DCFDA, general ROS indicator. Graph shows averaged traces of cell responses to ALS IgG 
(sample #16; green trace) or control IgG (sample #28; orange trace) for 10 min, followed by washing step and treatment with 4 mM H2O2. The time of IgG treatment 
(0.1 mg/ml) is indicated by the gray box, while yellow box designates H2O2 action. Number of cells is indicated in the brackets. Note that fluorescence continues to 
increase even during the wash period in the case of ALS IgG, in contrast to control IgG, where it remains on the same level (indicated by arrows).
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In addition, several experiments were conducted with carboxy- 
H2DCFDA, a general ROS indicator. In this set of data, we used 
three ALS samples and one control (see Table  1 for details). 
One ALS and one control IgG induced slow rise in the fluores-
cence intensity of the ROS probe (Figure  6H). Note that the 
increase in fluorescence intensity started later for the control 
IgG (Figure 6H, orange trace), and remained on the same level 
during the washing step, while the generation of ROS contin-
ued even during washing in the case of ALS IgG (Figure  6H, 
green trace). The amplitudes of ALS- and control IgG-induced 
normalized fluorescence intensities (reflecting ROS generation) 
are statistically different throughout the application and wash 
period (two-tailed t-test on values in the same time points). 
Linear regression analysis showed also the difference in slopes 
during the IgG application (p < 0.0001; F = 347.42, DFn = 1, 
DFd =  19598). Two of the ALS samples did not induce any 
changes (data not shown).
DiscUssiOn
It is now widely accepted that the immune system has a role 
in ALS. Thus, a persistent and prominent activation of innate 
(e.g., complement activation) and adaptive (e.g., IgG secretion) 
immunity was noted, followed by T lymphocytes of the helper/
inducer (CD4+), and in later disease phase, by cytotoxic/suppressor 
(CD8+) subtypes (4, 49, 50). A large body of experimental 
studies also indicates the specificity of ALS IgGs and their effect 
on neuronal and non-neuronal cells (21, 25, 51, 52). However, 
the binding site of ALS IgGs and the triggering mechanism 
remains elusive. As to the binding of IgG, there have been past 
attempts to ascribe it to Ca2+ channels (53–56) and the binding 
was evidenced in the presynaptic space of the motor plate (56). 
In addition, we and others have suggested a Ca2+ signaling 
mechanism underlying the ALS IgG effect (19, 21, 56, 57). 
Nevertheless, recently it has also been shown that ALS IgG can 
bind to the CD16 receptor on microglia or lymphocytes as well 
as to the immune synapse between the microglia and the neuron 
(58, 59).
Numerous studies demonstrate that microglial cells in the 
spinal cord and in the cerebral cortex become activated with the 
disease progression (2, 60, 61), which is now, along with astrocyte 
activation, considered to be one of the main characteristics of ALS 
(62). In this study we showed that ALS IgGs can induce a release 
of proinflammatory factors, ROS production and oxidative stress 
and upregulate antioxidative system in the microglial BV-2 cell 
line, which has been shown to be an appropriate experimental 
model for in vitro studies of cellular mechanisms of microglial 
activation (63, 64).
BV-2 Microglia releases TnF-α in 
response to als igg
TNF-α is a proinflammatory cytokine that is released in large 
amounts by microglia in pathological conditions, and this de 
novo production is considered to be an important feature of 
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neuroinflammatory response associated with neurodegen-
erative diseases (65). While an earlier study has shown that 
intraperitoneal injection of ALS IgG in mice resulted in the 
activation of microglia (66), a more recent study detected 
an increased release of TNF-α in the spinal cords of animals 
inoculated with ALS IgG (24). Our experiments are in line 
with previous finding, as we demonstrated a significant 
release of TNF-α after 24 h treatment of BV-2 cells with ALS 
IgG (Figure 4A), and stress out the contribution of microglia 
to the ALS IgG-induced inflammatory response. Elevated 
levels of TNF-α could potentiate glutamate excitotoxicity, a 
well-established fact in ALS, either influencing the balance 
of excitatory and inhibitory receptors on neurons, or indi-
rectly by inhibiting glutamate uptake by astrocytes (65). Our 
immunocytochemistry experiments showed that both ALS 
IgG and control IgG have similar binding patterns on the cell 
surface of the BV-2 cells (Figure 5). Therefore, we excluded the 
possibility that effects on TNF-α release, as well as the other 
results presented in this study, were due to direct intracellular 
effects of these humoral factors. However, further experiments 
have to be carried out in order to reveal the differences in the 
signaling pathways of ALS IgG and control IgG. In our study, 
no difference was detected in gene expression level of TNF-α 
(Figure 4B), which is probably due to a relatively short treat-
ment with IgG (4  h). Our previous study on BV-2 cells has 
shown that LPS induced changes in TNF-α gene expression 
(67), which is in disagreement with this finding. However, this 
difference may be due to different types of activator molecules 
and therefore possible differences in signaling pathways. 
Nevertheless, we were able to detect a dramatic increase in 
TNF-α gene expression of BV-2 cells even after 4  h of treat-
ment with IgG from a fALS patient (sample #3, Table 1) with 
mutation in SOD1 and ALSFRSr 45 (red dot, Figure 4B). This 
outlier result may indicate a potential functional difference in 
IgGs from sALS and fALS patients that prompts a future study 
toward a differential disease marker. Notably, it was found that 
a variant of exogenous mutant SOD1 (G93A) protein could 
also induce a release of TNF-α in microglia that could induce 
toxicity to motor neurons via TLR and CD14 pathways (68). 
Taken together, further investigations are necessary in order 
to determine the signal cascade(s) that ALS IgG initiates in 
microglial cells, and potential differences or similarities in the 
mechanism(s) of action of sALS and fALS IgG.
als igg have Potency to induce Oxidative 
stress in BV-2 cells
As a further proof of microglial humoral activation the results 
of this study show that the NO production was significantly 
increased in BV-2 cells by ALS IgG (Figure 1B). These results 
are in agreement with a previous study on the ALS animal 
model showing that the disease progression is followed by an 
increase in the number of microglial cells expressing inducible 
nitrate oxide synthase (69). While the effect of NO might be 
overestimated in vitro where there is no drain for this molecule, 
NO diffuses to red blood cells in tissue within seconds, where 
interacts with oxyhemoglobine (70). Nevertheless, while NO 
is moderately toxic, high concentrations may out-compensate 
SOD, and it may react with the superoxide anion to form 
peroxynitrite, that can selectively oxidize certain biological 
macromolecules, a mechanism pointing to a common cause of 
in vitro motor neuron death (71). In addition, we observed a 
significant increase of the index of lipid peroxidation (MDA 
production; Figure 1B), another confirmation of our hypothesis 
that ALS IgG can induce oxidative stress, that was in agreement 
with results obtained in vivo and ex vivo from brainstem and 
hippocampus of hSOD1(G93A) rats (32). Wu et al. (61) showed 
that NOX is activated in spinal cords of ALS patients and animal 
model of the disease, where NOX driven oxidant products from 
activated microglial cells impair the survival pathways of motor 
neurons, linking oxidative stress with neuronal death in ALS. 
Interestingly, our study has found increased NOX2 expression 
even after 4  h of treatment with one fALS (SOD1D90A) IgG 
(red dot Figure  3D), stressing out the need for additional 
experiments that might define the mechanism(s) underlying 
potential functional differences between familial and sporadic 
form of the disease.
antioxidative system is Upregulated  
after Treatment with als igg
This study shows that the activity of MnSOD and Cu/ZnSOD 
was elevated after the treatment with ALS IgG (Figures 2A,B), 
as well as CAT (Figure  2C), but without a change in gene 
expression after 4 h treatment (Figure 3B). As a consequence of 
oxidative stress in an in vitro model of microglial activation with 
LPS, protein expression of MnSOD and Cu/ZnSOD was also 
increased (72). Therefore, we can assume that the antioxidative 
defense in BV-2 cells is upregulated as a result of the microglial 
activation and/or oxidative stress induced by ALS IgG. Analysis 
of gene expression of MnSOD after 4 h treatment did not show 
any change, although again the same outlier sample from the 
fALS patient (score 45) induced an increase in gene expression. 
Interestingly, as this fALS patient has mutated SOD1, these 
data are in agreement with elevated activity of MnSOD in the 
brainstem and hippocampus of hSOD1G93A rats, already in 
the presymptomatic stage (32). This could be explained as a 
compensatory mechanism of antioxidative defense when SOD1 
activity is reduced due to mutation, and oxidative stress is 
most probably increased. In addition, we found that the total 
glutathione level was significantly decreased due to ALS IgG 
treatment compared with untreated cells (Figure 2F). A char-
acteristic of in vitro microglial stimulation with LPS and IFNγ, 
as well as in oxidative stress is a decrease in total glutathione 
level (73, 74). These data underline that ALS IgG induces oxida-
tive stress in BV-2 cells. Regarding the antioxidative defense an 
upregulation was observed as a rise in GR activity following the 
ALS IgG treatment (Figure 2E). On the other hand, we observed 
a significantly decreased GPx activity (Figure  2D) compared 
with untreated cells, and there was no change in the gene 
expression level compared with both groups (Figure 3C). One 
might speculate that while the increase in the GR activity reflects 
upregulation of antioxidative system, the decrease in GPx activ-
ity might be the consequence of the decrease in substrate, as 
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the total glutathione levels decrease. The role of GPx in ALS, 
however, is controversial because different studies showed that 
its activation and expression in spinal cord and cerebral cortex 
of patients can be decreased (75), without change compared 
with the control group (76) or not detectable at all (77).
We were unable to detect a change in gene expression for 
NOX2 after the treatment with ALS IgG (Figure 3D), which is 
in disagreement with results that show an upregulation of NOX2 
in an animal model with the disease progression (61). The pos-
sible explanation of this discrepancy could be that it might take 
more than 4  h of ALS IgG treatment for the change in NOX2 
expression or any other gene considered in this study. It is also 
worth mentioning that the sample from the fALS patient (with 
mutation in SOD1D90A, and ALSFRSr of 45) induced a rise in 
gene expression of NOX2, as well as of MnSOD and TNF-α, again 
indicating a possible differential marker for sALS and fALS that 
needs to be further studied.
acute rOs Production is induced  
by als igg
Our imaging experiments on single cell responses to acute 
application of ALS IgGs revealed an expected heterogeneity of 
reactions, having in mind the heterogeneity of sALS patients in 
terms of, e.g., clinical course, disease duration and response to 
pharmacological treatment. The common denominator of all 
experiments is that roughly one third of ALS samples show a 
well-defined rise in the signal for pH-sensitive (SypHer, HyPer) 
and peroxide sensitive (HyPer) genetically encoded indicators, as 
well as for ROS-sensitive probe (Carboxy-H2DCFDA). Although 
not significantly different from pH change in all studied cases, the 
peroxide response with HyPer was always on top of pH-specific 
SypHer signal. The ALS IgG-induced ROS generation was sig-
nificantly higher than control IgGs-induced, as confirmed with 
carboxy-H2DCFDA. The difference in ROS generation during 
the washout period between those two types of IgG (Figure 6G, 
indicated by arrows) might indicate stronger or more specific 
binding of ALS IgG to the still unknown BV-2 membrane antigen. 
Nevertheless, alkalization of the cytoplasm induced by ALS IgGs 
is also a sign of antioxidative defense by way of proton extrusion 
(78) where NHE1 was suspected as a key transporter (48). We 
have thus, checked the gene expression for NHE1 after 4 h ALS 
IgG-treatment, but were unable to detect a change in mRNA 
(Figure  3E), possibly due to the short treating period. Hence, 
additional experiments would be needed to confirm or exclude 
the role of NHE1 in the activation of microglia by ALS IgG.
The present study in an in vitro setup provides a missing link 
between the oxidative stress in ALS and many different actions of 
humoral factors in the underlining neuroinflammation. It focuses 
on microglial cells as key players of the inflammatory response 
and highlights ALS IgG-induced ROS generation as the trigger 
of activation of initially healthy microglia. Revealing the ALS IgG 
signaling cascade in microglial cells could offer valuable molecu-
lar biomarkers and/or potential therapeutic targets. Namely, such 
biomarkers could be followed in microglial cells from patients 
(i.e., derived form inducible pluripotent stem cells) under no or 
standard stimulation (e.g., with ATP or H2O2) or as shown here, 
healthy cells (preferably of human origin) could be used to test 
ALS IgGs for better disease profiling.
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